로딩 중…
지수 로딩 중…
KoBioLabs, Inc.
348150· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩3,600-6.25%
2026-06-19
Price Chart
KoBioLabs, Inc.-26.38%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 69.91B KRW |
| Revenue | 71.21B KRW |
| Net Income | -1.13B KRW |
| Total Assets | 90.80B KRW |
| Net Assets | 46.99B KRW |
| Employees | 57 |
| Value | |
| P/B | 1.49x |
| P/S | 0.98x |
| FCF Yield | -8.70% |
| Profitability | |
| ROE | -2.41% |
| ROA | -1.25% |
| Op. Margin | -13.55% |
| Revenue Growth | 11.10% |
| Financial Health | |
| Debt Ratio | 93.25% |
| Total Debt | 16.26B KRW |
| FCF | -6.08B KRW |
| Cash | 7.07B KRW |
| Current Ratio | 3.91x |
| Performance | |
| 1Y Return | -26.38% |
| 1M Return | -15.89% |
| From 52W High | -58.76% |
| 1Y MDD | -49.78% |
| Trading | |
| Volume | 71,087 shares |
| Foreign Own. | 2.90% |
| Per Share | |
| EPS | -190 KRW |
| BPS | 1,546 KRW |
Company Info
KoBioLabs, established in 2014 and listed on KOSDAQ in 2020, is a microbiome-specialized biotech company. It develops human microbiome-based therapeutics like CUREbiotics and operates a health functional food business, producing and selling probiotic products via its subsidiary, WeBiome. Through its Smartiome 2.0 new drug development platform, the company has established a therapeutic pipeline for immune diseases and secured core competitiveness in the bio sector by commencing global clinical trials for microbiome new drugs.